PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11211149-4	2001	The advantages of IFN-alpha therapy were most marked in studies using anthracycline-containing induction chemotherapy; in these studies, patients who received IFN-alpha had approximately 20% increased progression-free survival rates compared with controls and a lesser survival advantage.	Anthracyclines	70-83	interferon alpha 1	Homo sapiens	18-27	
11211149-4	2001	The advantages of IFN-alpha therapy were most marked in studies using anthracycline-containing induction chemotherapy; in these studies, patients who received IFN-alpha had approximately 20% increased progression-free survival rates compared with controls and a lesser survival advantage.	Anthracyclines	70-83	interferon alpha 1	Homo sapiens	159-168	
8692529-2	1996	Preclinical studies also showed an enhancement of FU and anthracyclines with interferon.	Anthracyclines	57-71	interferon alpha 1	Homo sapiens	77-87